Literature DB >> 9797215

Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice.

T Matsumoto1, K Tateda, S Miyazaki, N Furuya, A Ohno, Y Ishii, Y Hirakata, K Yamaguchi.   

Abstract

We evaluated the protective effect of interleukin-10 (IL-10) against murine gut-derived sepsis caused by Pseudomonas aeruginosa. Gut-derived sepsis was induced by administering cyclophosphamide and ampicillin while feeding P. aeruginosa to specific-pathogen-free mice. Treating mice with recombinant human IL-10 (rhIL-10) at 1.0 or 5.0 microg/mouse twice a day following the second cyclophosphamide administration significantly increased the survival rate compared to that of control mice treated with saline; however, treatment with rhIL-10 at 0.1 microg/mouse did not result in significant protection. Bacterial counts in the liver, spleen, and blood were all significantly lower in mice treated with rhIL-10 than in saline-treated control mice. Treatment with rhIL-10 significantly suppressed tumor necrosis factor alpha, interleukin-1beta, interleukin-6, and gamma interferon levels in the serum of mice following induction of gut-derived sepsis. We also studied the effect of IL-10 on leukocyte recovery after cyclophosphamide treatment of mice. Administration of rhIL-10 intraperitoneally at 1. 0 microg/mouse significantly accelerated the recovery of leukocytes in comparison with that of the group of saline-treated controls. These results indicate that IL-10 shows a protective effect against gut-derived P. aeruginosa sepsis. We suspect that the mechanism of this effect is that IL-10 regulates in vivo production of inflammatory cytokines. Furthermore, acceleration of leukocyte recovery by IL-10 after cyclophosphamide-induced depression may also play an important role in this protection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797215      PMCID: PMC105955     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice.

Authors:  Y Hirakata; M Kaku; K Tomono; K Tateda; N Furuya; T Matsumoto; R Araki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages.

Authors:  R T Gazzinelli; I P Oswald; S L James; A Sher
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

3.  IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression.

Authors:  L Ding; P S Linsley; L Y Huang; R N Germain; E M Shevach
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

4.  Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans.

Authors:  L Romani; P Puccetti; A Mencacci; E Cenci; R Spaccapelo; L Tonnetti; U Grohmann; F Bistoni
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

Review 5.  Properties and functions of interleukin-10.

Authors:  T R Mosmann
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

6.  Paradoxical synergistic effects of tumour necrosis factor and interleukin 1 in murine gut-derived sepsis with Pseudomonas aeruginosa.

Authors:  T Matsumoto; K Tateda; S Miyazaki; N Furuya; A Ohno; Y Ishii; Y Hirakata; K Yamaguchi
Journal:  Cytokine       Date:  1999-05       Impact factor: 3.861

7.  Treatment with anti-interleukin-10 monoclonal antibody enhances early resistance to but impairs complete clearance of Listeria monocytogenes infection in mice.

Authors:  R D Wagner; N M Maroushek; J F Brown; C J Czuprynski
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

8.  IL-10 neutralization augments mouse resistance to systemic Mycobacterium avium infections.

Authors:  M Denis; E Ghadirian
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

9.  Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia.

Authors:  C Gérard; C Bruyns; A Marchant; D Abramowicz; P Vandenabeele; A Delvaux; W Fiers; M Goldman; T Velu
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

10.  Interleukin 10 protects mice from lethal endotoxemia.

Authors:  M Howard; T Muchamuel; S Andrade; S Menon
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  4 in total

1.  Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice.

Authors:  Ryohei Watanabe; Tetsuya Matsumoto; Go Sano; Yoshikazu Ishii; Kazuhiro Tateda; Yoshinobu Sumiyama; Jumpei Uchiyama; Shingo Sakurai; Shigenobu Matsuzaki; Shosuke Imai; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Translocation of Pseudomonas aeruginosa from the intestinal tract is mediated by the binding of ExoS to an Na,K-ATPase regulator, FXYD3.

Authors:  Jun Okuda; Naoki Hayashi; Masashi Okamoto; Shinji Sawada; Shu Minagawa; Yoshitaka Yano; Naomasa Gotoh
Journal:  Infect Immun       Date:  2010-08-30       Impact factor: 3.441

Review 3.  The bioartificial kidney in the treatment of acute kidney injury.

Authors:  Joon Ho Song; H David Humes
Journal:  Curr Drug Targets       Date:  2009-12       Impact factor: 3.465

4.  The Efficacy of Phage Therapy in a Murine Model of Pseudomonas aeruginosa Pneumonia and Sepsis.

Authors:  Xu Yang; Anwarul Haque; Shigenobu Matsuzaki; Tetsuya Matsumoto; Shigeki Nakamura
Journal:  Front Microbiol       Date:  2021-07-05       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.